Spesolimab: a comprehensive review on the anti‐IL‐36 receptor antibody in dermatology

Abstract

Interleukin‐36 (IL‐36) cytokines contribute to the pathogenesis of various inflammatory skin conditions and are potential therapeutic targets. Spesolimab is a monoclonal antibody that inhibits IL‐36 signaling recently approved by the Food and Drug Administration for the management of generalized pustular psoriasis flares in adults. Clinical trials are evaluating the efficacy of this monoclonal antibody in a few other dermatological conditions. Here, this review comprehensively summarizes the safety and efficacy of spesolimab treatment in various dermatological conditions.

Generalized Pustular Psoriasis of Pregnancy Successfully Treated With Certolizumab Pegol: A Case Report and Literature Review

“…While the pathophysiological role of TNF-α in plaque psoriasis is well established, IL-36 is believed to play a crucial role in generalized pustular psoriasis [8]. By binding to its receptor (IL-1RL2), IL-36 activates the nuclear factor-κB signaling pathway, leading to increased production of proinflammatory cytokines such as IL-1, IL-6, and IL-8 [4,8]. The IL-36 receptor antagonist (IL36RN) is a protein that counteracts the inflammatory effects of IL-36.…”

“…Currently, the IL-36 receptor antagonist spesolimab is the only biologic drug approved for treating GPP in the United States and Europe. However, it is not licensed for use during pregnancy [8] and is currently unavailable in Germany.…”